# A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects

> **NCT07400744** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 102 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** QL2109
- **DRUG:** Darzalex

## Key facts

- **NCT ID:** NCT07400744
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2026-09
- **Final completion:** 2026-10
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07400744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07400744, "A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07400744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*